RxDoctor Payments Data

Warren Johnson

Family Medicine · Phoenix, AZNPI 1134168925

Payments from drug & device makers

$13,247in general payments, 2019–2025

Across 792 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$1K
  • Pfizer$1K
  • Boehringer Ingelheim$665
  • Lilly USA, LLC$567
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$473
  • plus $6K from 54 others
$150in research payments, 2019–2025

Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Indivior Inc.$150

What the payments were for

  • Travel & lodging$901%
  • Food & beverage$13,07299%
  • Education$851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)243$3,231
AstraZeneca48$1,294
Pfizer76$1,038
Boehringer Ingelheim37$665
Lilly USA, LLC36$567
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC31$473
Novo Nordisk29$450
Astellas Pharma US Inc18$444
Abbott19$393
Takeda Pharmaceuticals U.S.A., Inc.24$361
GSK17$284
Johnson & Johnson12$233
Dexcom, Inc.10$217
Amgen(2 entities)11$203
Otsuka America Pharmaceutical, Inc.9$200
Novartis11$177
Exact Sciences8$165
Almatica Pharma LLC7$151
Axsome Therapeutics, Inc.7$138
Biosense Webster, Inc.1$124
Lundbeck LLC7$122
Eisai Inc.8$121
Bayer8$118
Nestle Healthcare Nutrition Inc.9$113
E.r. Squibb & Sons, L.L.C.6$109
Boston Scientific4$100
Shield Therapeutics Inc4$96
Merck6$87
Currax Pharmaceuticals LLC6$86
Biohaven Pharmaceuticals, Inc.4$81
Arbor Pharmaceuticals, Inc.6$81
Vanda Pharmaceuticals Inc.4$72
Teva Pharmaceuticals USA, Inc.3$70
Idorsia Pharmaceuticals US Inc4$64
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$61
Kowa Pharmaceuticals America, Inc.3$61
Biohaven Pharmaceutical Holding Company Ltd.3$60
Aimmune Therapeutics, Inc.3$59
Esperion Therapeutics, Inc.3$57
Impel Pharmaceuticals Inc.2$56
Medtronic2$54
Edwards Lifesciences2$51
Scilex Pharmaceuticals Inc.3$51
Genentech USA, Inc.3$47
Therapeuticsmd, Inc.3$38
Hologic Sales And Service, LLC1$36
Saluda Medical Americas, Inc.1$33
Abiomed1$32
Optinose US, Inc.1$31
Amarin Pharma, Inc.2$31
Acella Pharmaceuticals, LLC2$30
Cranial Technologies, Inc2$30
Mayne Pharma Commercial LLC1$29
Si-bone, Inc.1$22
Phadia US Inc.1$22
Phathom Pharmaceuticals, Inc.1$22
IBSA Pharma Inc.1$20
Xeris Pharmaceuticals, Inc.1$19
Tonix Medicines, Inc.1$17
Halozyme Inc1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,247 in reported general payments places this provider in the 95th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$236,147
Medicare patients
926
Services billed
2,406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin73$68,164
EliquisApixaban81$64,664
OzempicSemaglutide43$48,008
OxycontinOxycodone Hcl19$46,431
FarxigaDapagliflozin Propanediol44$43,028
MounjaroTirzepatide35$36,598
Oxymorphone Hcl ErOxymorphone Hcl15$34,038
XareltoRivaroxaban30$33,961
JanuviaSitagliptin Phosphate16$20,452
UbrelvyUbrogepant11$17,889
Xtampza ErOxycodone Myristate14$16,499
MyrbetriqMirabegron15$16,155
TradjentaLinagliptin12$11,363
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,218
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$9,189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$665$79,52885 claims
PfizerEliquis$1,038$64,66481 claims
AstraZenecaFarxiga, Symbicort$1,294$49,64562 claims
Novo NordiskOzempic$450$48,00843 claims
Lilly USA, LLCMounjaro$567$36,59835 claims
Johnson & JohnsonXarelto$233$33,96130 claims
AbbVieUbrelvy, Linzess, Synthroid$3,231$30,05574 claims
MerckJanuvia$87$20,45216 claims
Astellas Pharma US IncMyrbetriq$444$16,15515 claims
GSKTrelegy Ellipta$284$10,21816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →